Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections. It also offers licensed and owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinsons Disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The company has operations in the United States, Switzerland, India, Ireland, the United Kingdom and internationally. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone908-947-3120
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.86 billion
Profitability
Miscellaneous
Employees6,000
Next Earnings Date5/9/2019 (Confirmed)
OptionableOptionable
Amneal Pharmaceuticals (NYSE:AMRX) Frequently Asked Questions
What is Amneal Pharmaceuticals' stock symbol?
Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."
How were Amneal Pharmaceuticals' earnings last quarter?
Amneal Pharmaceuticals Inc (NYSE:AMRX) posted its quarterly earnings data on Thursday, February, 28th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.06. The business earned $497.53 million during the quarter, compared to analysts' expectations of $478.06 million. Amneal Pharmaceuticals had a net margin of 1.84% and a return on equity of 25.73%. View Amneal Pharmaceuticals' Earnings History.
When is Amneal Pharmaceuticals' next earnings date?
How can I listen to Amneal Pharmaceuticals' earnings call?
Amneal Pharmaceuticals will be holding an earnings conference call on Thursday, May 9th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.
What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?
Amneal Pharmaceuticals updated its FY19 earnings guidance on Thursday, February, 28th. The company provided earnings per share (EPS) guidance of $0.94-1.04 for the period, compared to the Thomson Reuters consensus estimate of $1.22. Amneal Pharmaceuticals also updated its FY 2019 guidance to $0.94-1.04 EPS.
What price target have analysts set for AMRX?
11 equities research analysts have issued 1-year price targets for Amneal Pharmaceuticals' shares. Their predictions range from $12.00 to $35.00. On average, they expect Amneal Pharmaceuticals' share price to reach $20.7778 in the next year. This suggests a possible upside of 61.6% from the stock's current price. View Analyst Price Targets for Amneal Pharmaceuticals.
What is the consensus analysts' recommendation for Amneal Pharmaceuticals?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amneal Pharmaceuticals.
What are Wall Street analysts saying about Amneal Pharmaceuticals stock?
Here are some recent quotes from research analysts about Amneal Pharmaceuticals stock:
- 1. Cantor Fitzgerald analysts commented, ". We reiterate our OW rating and 12-month PT of $35 for AMRX shares post a 4Q18 beat and despite lower than anticipated guidance for 2019. We still believe that AMRX will be able to successfully grow from a mid-size generics company into a leading generics and specialty pharma company. Therefore, upward earnings revisions in 2020+ should drive the stock higher. These upward earnings revisions should come from: 1) new generic drug launches, 2) operating margin expansion, 3) high-margin brand drug sales, and 4) strategic M&A as well as tuck-in deals." (2/28/2019)
- 2. According to Zacks Investment Research, "Amneal Pharmaceuticals LLC is an integrated specialty pharmaceutical company. It focused on developing, manufacturing and distributing generic, brand and biosimilar products. The company operates primarily in North America, Asia and Europe. Amneal Pharmaceuticals LLC, formerly known as Impax Laboratories Inc., is based in New Jersey, United States. " (1/14/2019)
- 3. Canaccord Genuity analysts commented, "We expect the deal to bring accretion starting in 2Q/19, which should help contribute to achieving the long-term goals that management set at the Impax/Amneal announcement, of double-digit revenue and EPS growth through 2020. In addition, we believe the deal is evidence of Amneal’s deal- making prowess that could result in further creative transactions moving forward. That said, as the core business continues to perform, we expect sentiment to improve on AMRX shares as the newco puts a number of quarters under its belt. We’re waiting on the sidelines as we watch the company continue to evolve; maintain HOLD. Deal consolidates branded and generic JSP levo products. The transaction gives Amneal access to JSP’s generic levothyroxine, an approximately $200 million run-rate product, in addition to the branded Unithroid Amneal already distributes for JSP." (8/20/2018)
- 4. Guggenheim analysts commented, "We were not including it in our prior estimates and are now increasing our revenue and adjusted EPS estimates." (5/18/2018)
Has Amneal Pharmaceuticals been receiving favorable news coverage?
Media stories about AMRX stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Amneal Pharmaceuticals earned a news sentiment score of 1.6 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term.
Who are some of Amneal Pharmaceuticals' key competitors?
Some companies that are related to Amneal Pharmaceuticals include Teva Pharmaceutical Industries (TEVA), BioMarin Pharmaceutical (BMRN), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), Mylan (MYL), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Ionis Pharmaceuticals (IONS), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Marina Biotech (MRNA), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Jazz Pharmaceuticals (JAZZ) and Beigene (BGNE).
What other stocks do shareholders of Amneal Pharmaceuticals own?
Who are Amneal Pharmaceuticals' key executives?
Amneal Pharmaceuticals' management team includes the folowing people:
- Mr. Paul M. Bisaro, Exec. Chairman (Age 58)
- Mr. Chirag K. Patel, Co-Founder & Co-Chairman (Age 52)
- Mr. Chintu Patel, Co-Founder & Co-Chairman (Age 47)
- Mr. Robert A. Stewart, Pres, CEO & Director (Age 51)
- Ms. Nikita Shah, Sr. VP & Chief HR Officer (Age 41)
Who are Amneal Pharmaceuticals' major shareholders?
Amneal Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Tibra Equities Europe Ltd (0.02%), Eqis Capital Management Inc. (0.01%), Brinker Capital Inc. (0.01%) and Meeder Asset Management Inc. (0.00%). Company insiders that own Amneal Pharmaceuticals stock include Bryan M Reasons, Nikita Shah, Paul Bisaro and Peter R Terreri. View Institutional Ownership Trends for Amneal Pharmaceuticals.
Which major investors are selling Amneal Pharmaceuticals stock?
AMRX stock was sold by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. Company insiders that have sold Amneal Pharmaceuticals company stock in the last year include Bryan M Reasons, Nikita Shah and Peter R Terreri. View Insider Buying and Selling for Amneal Pharmaceuticals.
Which major investors are buying Amneal Pharmaceuticals stock?
How do I buy shares of Amneal Pharmaceuticals?
Shares of AMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amneal Pharmaceuticals' stock price today?
One share of AMRX stock can currently be purchased for approximately $12.86.
How big of a company is Amneal Pharmaceuticals?
Amneal Pharmaceuticals has a market capitalization of $3.84 billion and generates $1.86 billion in revenue each year. The company earns $-169,730,000.00 in net income (profit) each year or $0.95 on an earnings per share basis. Amneal Pharmaceuticals employs 6,000 workers across the globe.
What is Amneal Pharmaceuticals' official website?
How can I contact Amneal Pharmaceuticals?
Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-947-3120 or via email at [email protected]
MarketBeat Community Rating for Amneal Pharmaceuticals (NYSE AMRX)
MarketBeat's community ratings are surveys of what our community members think about Amneal Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
